EKF Diagnostics Holdings plc –
Group Statement of Compliance with
The Modern Slavery Act 2015

Introduction

EKF Diagnostics Holdings plc and its Subsidiary Companies, EKF Diagnostics GmbH and Stanbio Laboratories, operates in a number of countries including the UK. We are committed to ensuring that exploitation with regards to any form of Slavery or Human Trafficking does not take place in any part of our business or supply chain.

Section 54, Part 6 of the Modern Slavery Act 2015 (the ‘Act’) requires all organisations to set out the steps the organisation has taken during the financial year to ensure that slavery and human trafficking is not taking place within either its UK business or the supply chains to that business.

Organisational Structure

EKF Diagnostics Holdings plc consists of several wholly owned subsidiaries including Stanbio Laboratory LP, Separation Technology Inc., EKF Diagnostics GmbH, SensLab GmbH, DiaSpect Medical GmbH, EKF Diagnostyka Sp.z.o.o. This Corporate statement of compliance is valid and effective for all wholly owned subsidiaries of the parent company.

The Group operates inside and outside of the United Kingdom and have a combined annual turnover in excess of £36m.

Our Business

EKF Diagnostics is a global medical diagnostics business with a long history in point-of-care testing and manufacturing reagents for use in central laboratories.

Our point-of-care (POC) products, most of which are designed and manufactured in Germany, have a hard earned reputation for ease of use, reliability and accuracy from professionals working in diabetes, blood banking and sports medicine.

Through Stanbio Laboratory, we have built a global customer base for its clinical chemistry reagents that can be used on most open-channel analyser platforms. The business also includes the manufacture of enzymes and hematology products.

Our Policy

We are committed to ensuring that there is no modern slavery within our business, in our supply chain or with the distributors that we deal with. We aim to demonstrate that the EKF Diagnostics Group follows good practice and all reasonable steps are taken to prevent slavery and human trafficking. We believe that all individuals who work within our business should be treated with dignity and respect, rewarded fairly for their work and not exploited. We only wish to work with organisations in our supply chain that have similar commitment and are not involved in modern slavery.
Our Supply Chains

We expect all parties in our supply chain to comply with our values. We will commence a process of actively seeking confirmation from our supply chain third parties and distributors (UK and overseas). All suppliers are required to ensure that they provide employees with good working conditions, fair treatment and reasonable rates of pay and that they respect workers’ human rights and comply with local labour laws and regulations. Serious violations will lead to the termination of the business relationship.

Activities to be undertaken in the next 12 months

A more detailed risk assessment of direct material suppliers will be undertaken.

The introduction of contractual clauses - the Company will be drafting and introducing standard contract clauses that will require compliance with the Act.

Training

The Board of Directors understands their responsibilities and relevant Group employees will receive guidance over the next year to fully understand their responsibility to be alert to the risks in our business and in the wider supply chains.

Training will be developed and delivered to all appropriate personnel, targeting those areas of the business which the Company identifies as posing the greatest risk from a slavery or human trafficking perspective.

Staff will be instructed that they are expected to report concerns, with management being tasked to act upon any concerns.

We already have in place an appropriate reporting framework to encourage the reporting of concerns and to ensure the protection of whistle blowers. All reports will be fully investigated and appropriate remedial actions taken.

Board of Director’s Approval

This statement has been approved by the Board of Directors of EKF Diagnostics Holdings plc.

Julian Baines
Chief Executive Officer
April 2017